Verona Pharma PLCNASDAQ:VRNA
- LAST PRICE12.4000
- TODAY'S CHANGE (%)0.3300 (2.7341%)
- Bid / Lots12.3600/ 62
- Ask / Lots12.4200/ 4
- Open / Previous Close12.5800 / 12.0700
- Day Range
- 52 Week Range
- Volume598,850
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VRNA |
|---|---|---|
| 09:32 ET | 65557 | 12.6 |
| 09:34 ET | 31405 | 12.575 |
| 09:36 ET | 5496 | 12.6 |
| 09:38 ET | 20757 | 12.58 |
| 09:39 ET | 700 | 12.575 |
| 09:41 ET | 5958 | 12.48 |
| 09:43 ET | 3765 | 12.38 |
| 09:45 ET | 29644 | 12.5 |
| 09:48 ET | 3349 | 12.48 |
| 09:50 ET | 14031 | 12.48 |
| 09:52 ET | 28009 | 12.47 |
| 09:54 ET | 3035 | 12.482 |
| 09:56 ET | 4853 | 12.48 |
| 09:57 ET | 42265 | 12.54 |
| 09:59 ET | 5744 | 12.51 |
| 10:01 ET | 6459 | 12.545 |
| 10:03 ET | 9750 | 12.505 |
| 10:06 ET | 26131 | 12.5 |
| 10:08 ET | 22251 | 12.475 |
| 10:10 ET | 16128 | 12.463 |
| 10:12 ET | 25183 | 12.51 |
| 10:14 ET | 2018 | 12.57 |
| 10:15 ET | 3767 | 12.6 |
| 10:17 ET | 1553 | 12.6 |
| 10:19 ET | 12394 | 12.49 |
| 10:21 ET | 4910 | 12.46 |
| 10:24 ET | 2225 | 12.48 |
| 10:26 ET | 1130 | 12.45 |
| 10:28 ET | 4290 | 12.495 |
| 10:30 ET | 9468 | 12.495 |
| 10:32 ET | 11322 | 12.5 |
| 10:33 ET | 15583 | 12.515 |
| 10:35 ET | 350 | 12.515 |
| 10:37 ET | 400 | 12.5 |
| 10:39 ET | 9900 | 12.49 |
| 10:42 ET | 10172 | 12.5 |
| 10:44 ET | 5378 | 12.47 |
| 10:46 ET | 989 | 12.41 |
| 10:48 ET | 1315 | 12.4 |
| 10:50 ET | 4580 | 12.36 |
| 10:51 ET | 300 | 12.345 |
| 10:53 ET | 500 | 12.325 |
| 10:55 ET | 7179 | 12.305 |
| 10:57 ET | 200 | 12.305 |
| 11:00 ET | 600 | 12.305 |
| 11:02 ET | 5530 | 12.315 |
| 11:04 ET | 400 | 12.315 |
| 11:06 ET | 1795 | 12.305 |
| 11:08 ET | 31460 | 12.27 |
| 11:09 ET | 800 | 12.33 |
| 11:11 ET | 24987 | 12.4 |
May 15, 2024
DJ Verona Pharma Price Target Maintained With a $32.00/Share by HC Wainwright & Co., from 6:10AM ET on Wednesday May 15, 2024 by Dow Jones
6:10AM ET on Wednesday May 15, 2024 by Dow Jones
May 13, 2024
DJ Verona Pharma Is Maintained at Buy by HC Wainwright & Co., from 11:04AM ET on Monday May 13, 2024 by Dow Jones
11:04AM ET on Monday May 13, 2024 by Dow Jones
May 9, 2024
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 7:15AM ET on Thursday May 09, 2024 by Dow Jones
7:15AM ET on Thursday May 09, 2024 by Dow JonesPress Release: Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 7:15AM ET on Thursday May 09, 2024 by Dow Jones
7:15AM ET on Thursday May 09, 2024 by Dow JonesVerona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS, from 7:00AM ET on Thursday May 09, 2024 by Dow Jones
7:00AM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Verona Pharma PLC | 978.7M | -15.7x | --- |
Centessa Pharmaceuticals PLC | 975.6M | -6.2x | --- |
Cassava Sciences Inc | 1.1B | -18.9x | --- |
Enliven Therapeutics Inc | 1.1B | -11.7x | --- |
Humacyte Inc | 890.8M | -7.4x | --- |
Perspective Therapeutics Inc | 881.0M | -9.0x | --- |
Company Information
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Contact Information
- Headquarters
- Riverside, 3 More London PlaceLONDON, United Kingdom SE1 2RE
- Phone
- 203-283-4200
- Fax
- 207-863-3314
Executives
- Non-Executive Independent Chairman of the Board
- David Ebsworth
- President, Chief Executive Officer, Executive Director
- David Zaccardelli
- Chief Financial Officer
- Mark Hahn
- General Counsel
- Claire Poll
- Chief Medical Officer
- Kathleen Rickard
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $978.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.34 |
EPS | $-0.79 |
Book Value | $3.10 |
P/E Ratio | -15.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
